[go: up one dir, main page]

WO2006079910A3 - 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity - Google Patents

0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity Download PDF

Info

Publication number
WO2006079910A3
WO2006079910A3 PCT/IB2006/000147 IB2006000147W WO2006079910A3 WO 2006079910 A3 WO2006079910 A3 WO 2006079910A3 IB 2006000147 W IB2006000147 W IB 2006000147W WO 2006079910 A3 WO2006079910 A3 WO 2006079910A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperidino
oral cavity
nicotinic
amixodime
treating lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/000147
Other languages
French (fr)
Other versions
WO2006079910A2 (en
Inventor
Andras Huszak
Orsolya Rigo
Balazs Zahonyi
Zsolt Lohinai
Kalman Tory
Attila Kolonics
Nagy Peter Literati
Tibor Bodnar
Sandor Bernath
Janos Egri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
N-Gene Research Laboratories Inc
Original Assignee
N-Gene Research Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N-Gene Research Laboratories Inc filed Critical N-Gene Research Laboratories Inc
Publication of WO2006079910A2 publication Critical patent/WO2006079910A2/en
Publication of WO2006079910A3 publication Critical patent/WO2006079910A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention refers to the use of of 0-(3-piperidino-2­hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition or a mouth and tooth care composition suitable for the treatment of lesions in the oral cavity.
PCT/IB2006/000147 2005-01-28 2006-01-20 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity Ceased WO2006079910A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0500145A HUP0500145A2 (en) 2005-01-28 2005-01-28 Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
HUP0500145 2005-01-28

Publications (2)

Publication Number Publication Date
WO2006079910A2 WO2006079910A2 (en) 2006-08-03
WO2006079910A3 true WO2006079910A3 (en) 2006-10-05

Family

ID=89985775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000147 Ceased WO2006079910A2 (en) 2005-01-28 2006-01-20 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity

Country Status (2)

Country Link
HU (1) HUP0500145A2 (en)
WO (1) WO2006079910A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN103301462B (en) * 2012-03-09 2015-06-03 海南康芝药业股份有限公司 Component and method for treating virus disease
CN108541948A (en) * 2018-07-16 2018-09-18 怀化学院 A kind of lithocarpus litseifolius lozenge and preparation method thereof
HUP1800298A1 (en) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Combination of beta blocker and hydroximic acid derivative with reduced side effects

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023198A1 (en) * 1995-12-22 1997-07-03 Medgene Limited A cosmetic composition and a method for reducing the ageing processes of skin
US6306878B1 (en) * 1995-09-29 2001-10-23 N-Gene Research Lab Inc Pharmaceutical compositions containing hydroximic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306878B1 (en) * 1995-09-29 2001-10-23 N-Gene Research Lab Inc Pharmaceutical compositions containing hydroximic acid derivatives
WO1997023198A1 (en) * 1995-12-22 1997-07-03 Medgene Limited A cosmetic composition and a method for reducing the ageing processes of skin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALMOSI R ET AL: "Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 59, no. 6, June 2001 (2001-06-01), pages 1497 - 1505, XP002360023, ISSN: 0026-895X *
LOHINAI Z ET AL: "Role of the activation of the nuclear enzyme poly(ADP-ribose) polymerase in the pathogenesis of periodontitis.", JOURNAL OF DENTAL RESEARCH. DEC 2003, vol. 82, no. 12, December 2003 (2003-12-01), pages 987 - 992, XP002391556, ISSN: 0022-0345 *
VIRAG L ET AL: "THE THERAPEUTIC POTENTIAL OF POLY(ADP-RIBOSE) POLYMERASE INHIBITORS", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 54, no. 3, 2002, pages 375 - 429, XP001121507, ISSN: 0031-6997 *

Also Published As

Publication number Publication date
WO2006079910A2 (en) 2006-08-03
HU0500145D0 (en) 2005-04-28
HUP0500145A2 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
EP2248519A3 (en) Non-mucoadhesive film dosage forms
IL197420A (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one, methods for its preparation, a pharmaceutical composition containing it and uses of such form in the preparation of medicaments for treatment of the human body
TW200637587A (en) Anti-caries oral care composition with xylitol
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2006007136A3 (en) Anti-microbial dental formulations for the prevention and treatment of oral mucosal disease
MY145790A (en) Composition
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
JP2011511793A5 (en)
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2005053719A3 (en) Compositions for the treatment of diseases of the oral cavity and upper respiratory tract
IL202111A (en) Formulations for the oral administration of amphotericin b and use thereof in the preparation of medicaments for treating an infectious disease
JP2012508256A5 (en)
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
WO2006004449A3 (en) A combination composition
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
UA90893C2 (en) Oral dosage forms of gemcitabine derivatives
JP2009500045A5 (en)
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2006079910A3 (en) 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity
TW200612922A (en) Inhibitors of hsp90
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
JP2009520694A5 (en)
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase

Ref document number: 06700551

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6700551

Country of ref document: EP